Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2025 09:00 ET | Source: ADARx Pharmaceuticals

ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors

ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors
November 26, 2025 04:00 ET | Source: Tangram Therapeutics PLC

Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate

The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA) submission marks the advancement of Tangram’s GalOmic RNAi...
November 03, 2025 08:45 ET | Source: SNS Insider pvt ltd

RNAi Technology Market to Reach USD 9.03 Billion by 2032, Driven by Advances in Gene Silencing and Therapeutic Applications – SNS Insider

Austin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- RNAi Technology Market Size & Growth Analysis According to SNS Insider, the global RNAi Technology Market was valued at USD 3.02 billion in 2024 and is...
October 01, 2025 07:00 ET | Source: Tangram Therapeutics PLC

e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS

Relaunch marks pivotal next step in the company’s growth, in anticipation of first CTA submission in Q4 2025. Introducing LLibra OS, a next-generation AI platform that accelerates discovery and...
September 04, 2025 16:28 ET | Source: ADARx Pharmaceuticals

ADARx Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

ADARx Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
August 08, 2025 16:03 ET | Source: NurExone Biologic Inc

NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard

TORONTO and HAIFA, Israel, Aug. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced that an independent study...
July 10, 2025 08:00 ET | Source: e-therapeutics plc

e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical Data

ETX-312 well tolerated at exaggerated dose levels in GLP-compliant toxicology studies GMP manufacturing of clinical trial batch successfully completed On track for CTA submission in Q4 2025 ...
May 07, 2025 09:00 ET | Source: e-therapeutics plc

e-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH

LONDON, May 07, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced it will...
February 10, 2025 09:16 ET | Source: Transparency Market Research

PCSK9 Inhibitor Market Growth Accelerates to USD 9.3 Billion by 2034, Driven by Innovative Cholesterol-Lowering Solutions | Latest Report by Transparency Market Research, Inc.

Wilmington, Delaware, United States, Transparency Market Research Inc.-, Feb. 10, 2025 (GLOBE NEWSWIRE) -- The PCSK9 Inhibitor Market (Markt für PCSK9-Inhibitoren) is poised for significant growth,...
February 05, 2025 08:00 ET | Source: e-therapeutics plc

e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025

LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, announced today that it will...